BEONE MEDICINES LTD. (ONC) FY2025 Annual Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2025-01-01 to 2025-12-31

Swipe to see the full flow
BEONE MEDICINES LTD. cash flow reconciliation, Jan 1, 2025 through Dec 31, 2025One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income (loss) → Net cash from operating activities: $286,933,000.00Share-based compensation expense → Operating adjustments reconciliation: $510,857,000.00Accrued expenses and other payables → Operating adjustments reconciliation: $311,762,000.00Depreciation and amortization expense → Operating adjustments reconciliation: $141,686,000.00Accounts payable → Operating adjustments reconciliation: $79,833,000.00Impairment of equity investments → Operating adjustments reconciliation: $75,626,000.00Other assets → Operating adjustments reconciliation: $37,164,000.00Other liabilities → Operating adjustments reconciliation: $18,968,000.00Non-cash interest expense → Operating adjustments reconciliation: $14,872,000.00Deferred income tax expense → Operating adjustments reconciliation: $9,469,000.00Deferred revenue → Operating adjustments reconciliation: $1,293,000.00Acquired in-process research and development → Operating adjustments reconciliation: $691,000.00Loss on long-term investments → Operating adjustments reconciliation: $596,000.00Operating adjustments reconciliation → Net cash from operating activities: $840,647,000.00Operating adjustments reconciliation → Accounts receivable: $164,954,000.00Operating adjustments reconciliation → Amortization of research and development cost share liability: $101,095,000.00Operating adjustments reconciliation → Inventories: $93,168,000.00Operating adjustments reconciliation → Other items, net: $2,953,000.00Proceeds from sale of future royalties → financing reconciliation: $911,000,000.00Proceeds from long-term loan → financing reconciliation: $850,586,000.00Proceeds from short-term loans → financing reconciliation: $233,676,000.00Proceeds from option exercises and employee share purchase plan → financing reconciliation: $196,281,000.00financing reconciliation → Net cash from financing activities: $1,059,451,000.00financing reconciliation → Repayment of short-term loans: $1,044,781,000.00financing reconciliation → Repayment of long-term loan: $35,680,000.00financing reconciliation → Payments of withholding taxes from share-based awards: $24,195,000.00financing reconciliation → Payments of debt issuance costs: $23,392,000.00financing reconciliation → Repayment of sale of future royalties liability: $4,044,000.00Net cash used in investing activities → investing reconciliation: $276,155,000.00Proceeds from sale or maturity of short-term investments → investing reconciliation: $3,446,000.00investing reconciliation → Purchases of property and equipment: $185,839,000.00investing reconciliation → Purchase of in-process research and development: $60,691,000.00investing reconciliation → Purchase of intangible assets: $20,000,000.00investing reconciliation → Purchase of long-term investments: $11,834,000.00investing reconciliation → Other investing activities: $1,237,000.00Exchange-rate effect → Cash sources and uses: $60,024,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $2,638,747,000.00Net cash from operating activities → Cash sources and uses: $1,127,580,000.00Net cash from financing activities → Cash sources and uses: $1,059,451,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $4,609,647,000.00Cash sources and uses → Net cash used in investing activities: $276,155,000.00Net income (loss): $286,933,000.00Net income (loss)+$286.93 MOther liabilities: $18,968,000.00Other operating liabilities+$18.97 MInventories: -$93,168,000.00Inventories−$93.17 MAccounts payable: $79,833,000.00Accounts payable+$79.83 MAmortization of research and development cost share liability: -$101,095,000.00R&D cost share liability amort.−$101.10 MOther items, net: -$2,953,000.00Other operating, net−$2.95 MOther assets: $37,164,000.00Other operating assets+$37.16 MAcquired in-process research and development: $691,000.00Acquired in-process R&D+$691.00 KDeferred income tax expense: $9,469,000.00Deferred taxes & credits+$9.47 MAccounts receivable: -$164,954,000.00Accounts receivable−$164.95 MDepreciation and amortization expense: $141,686,000.00Depreciation & amortization+$141.69 MImpairment of equity investments: $75,626,000.00Impairment of equity investments+$75.63 MLoss on long-term investments: $596,000.00Investment gain & loss+$596.00 KShare-based compensation expense: $510,857,000.00Stock-based compensation+$510.86 MDeferred revenue: $1,293,000.00Deferred revenue+$1.29 MAccrued expenses and other payables: $311,762,000.00Other payables & accruals+$311.76 MGain on BMS termination settlement: $0.00Non-cash interest expense: $14,872,000.00Non-cash interest expense+$14.87 MNet cash from operating activities: $1,127,580,000.00Operating cash+$1.13 BOperating adjustments reconciliation: $1,202,817,000.00Proceeds from sale of future royalties: $911,000,000.00Other debt issued+$911.00 MProceeds from long-term loan: $850,586,000.00Long-term credit line borrowings+$850.59 MRepayment of long-term loan: -$35,680,000.00Long-term debt repaid−$35.68 MProceeds from short-term loans: $233,676,000.00Short-term debt issued+$233.68 MRepayment of short-term loans: -$1,044,781,000.00Short-term debt repaid−$1.04 BPayments of debt issuance costs: -$23,392,000.00Debt issuance costs−$23.39 MPayments of withholding taxes from share-based awards: -$24,195,000.00Stock-award tax withholding−$24.20 MProceeds from option exercises and employee share purchase plan: $196,281,000.00Employee stock plans & options+$196.28 MRepayment of sale of future royalties liability: -$4,044,000.00Future royalty liability repaid−$4.04 MOther financing activities: $0.00Net cash from financing activities: $1,059,451,000.00Financing cash+$1.06 Bfinancing reconciliation: $2,191,543,000.00Purchase of long-term investments: -$11,834,000.00Long-term investment purchases−$11.83 MPurchases of property and equipment: -$185,839,000.00PP&E purchases−$185.84 MProceeds from sale or maturity of short-term investments: $3,446,000.00AFS securities sales+$3.45 MPurchase of intangible assets: -$20,000,000.00Intangible asset purchases−$20.00 MPurchase of in-process research and development: -$60,691,000.00In-process R&D purchases−$60.69 MOther investing activities: -$1,237,000.00Other investing, net−$1.24 MNet cash used in investing activities: -$276,155,000.00. Cash required to fund net payments.Investing cash−$276.16 Minvesting reconciliation: $279,601,000.00Cash sources and uses: $4,885,802,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $2,638,747,000.00Beginning cash$2.64 BEnding cash: Cash, cash equivalents, and restricted cash: $4,609,647,000.00Ending cash$4.61 BExchange-rate effect: $60,024,000.00FX effect+$60.02 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$941.74 MOperating cash − cash spent on PP&ECash flow / Net income3.93×Operating cash flow ÷ net incomeNet cash change+$1.97 BEnding cash − beginning cash
Chart details

BEONE MEDICINES LTD. cash flow reconciliation, Jan 1, 2025 through Dec 31, 2025

Cash flows for Jan 1, 2025 through Dec 31, 2025. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2024. Ending cash: Dec 31, 2025. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2024
2,638,747,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
1,127,580,000 US dollars. Net cash provided.
Net income (loss)
286,933,000 US dollars
Other liabilities
18,968,000 US dollars
Inventories
negative 93,168,000 US dollars
Accounts payable
79,833,000 US dollars
Amortization of research and development cost share liability
negative 101,095,000 US dollars
Other items, net
negative 2,953,000 US dollars
Other assets
37,164,000 US dollars
Acquired in-process research and development
691,000 US dollars
Deferred income tax expense
9,469,000 US dollars
Accounts receivable
negative 164,954,000 US dollars
Depreciation and amortization expense
141,686,000 US dollars
Impairment of equity investments
75,626,000 US dollars
Loss on long-term investments
596,000 US dollars
Share-based compensation expense
510,857,000 US dollars
Deferred revenue
1,293,000 US dollars
Accrued expenses and other payables
311,762,000 US dollars
Gain on BMS termination settlement
0 US dollars
Non-cash interest expense
14,872,000 US dollars
Investing activities
negative 276,155,000 US dollars. Net cash used.
Purchase of long-term investments
negative 11,834,000 US dollars
Purchases of property and equipment
negative 185,839,000 US dollars
Proceeds from sale or maturity of short-term investments
3,446,000 US dollars
Purchase of intangible assets
negative 20,000,000 US dollars
Purchase of in-process research and development
negative 60,691,000 US dollars
Other investing activities
negative 1,237,000 US dollars
Financing activities
1,059,451,000 US dollars. Net cash provided.
Proceeds from sale of future royalties
911,000,000 US dollars
Proceeds from long-term loan
850,586,000 US dollars
Repayment of long-term loan
negative 35,680,000 US dollars
Proceeds from short-term loans
233,676,000 US dollars
Repayment of short-term loans
negative 1,044,781,000 US dollars
Payments of debt issuance costs
negative 23,392,000 US dollars
Payments of withholding taxes from share-based awards
negative 24,195,000 US dollars
Proceeds from option exercises and employee share purchase plan
196,281,000 US dollars
Repayment of sale of future royalties liability
negative 4,044,000 US dollars
Other financing activities
0 US dollars
Operating adjustment reconciliation
1,202,817,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
2,191,543,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
279,601,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
60,024,000 US dollars
Ending cash on Dec 31, 2025
4,609,647,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
4,885,802,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
1,970,900,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
3.93×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
1,127,580,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
185,839,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
941,741,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $840.65M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 1,127,580,000 US dollars minus 185,839,000 US dollars equals 941,741,000 US dollars.
BEONE MEDICINES LTD. (ONC) FY2025 Annual Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!